Ursal, Kent B.

HRN: 22-41-36  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/08/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/08/2023
01/14/2023
IVT
35mg
OD
Neonatal Sepsis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: